Table 2.
HBcAb positive “only” patients characteristics
| |
|
Rituximab containing protocols |
|
|
|---|---|---|---|---|
| Variable | Overall | Yes | No | p |
| No. of patients |
96 |
48 |
48 |
ns |
| Age - Mean [±SD] |
64,39 ± 9,63 |
65,17 ± 10,21 |
64,02 ± 8,37 |
ns |
| Sex – M/F |
M: 57 |
M: 30 |
M: 27 |
ns |
| F: 39 |
F: 18 |
F: 21 |
||
| Lymphoma type |
Indolent: 50 |
Indolent: 17 |
Indolent: 33 |
0,001 |
| Aggressive: 46 |
Aggressive: 31 |
Aggressive: 15 |
||
| Probable OBI reactivation |
10 [10,42%] |
5 [10,42%] |
5 [10,42%] |
ns |
| NUC profilaxys/rescue therapy |
0/10 |
0/5 |
0/5 |
ns |
| “Per year Incidence of reactivation” [mean ± SD] |
8,23% ± 9,84 |
9,08% ± 10,69 |
11,54% ± 40,74 |
ns |
| Reactivation time [mean weeks after therapy] |
26,67 ± 12,20 |
31,60 ± 14,50 |
20,50 ± 4,72 |
ns |
| Liver related decompensations/hospitalizations/deaths | 0% | 0% | 0% | - |
No statistical differences were found in patients treated with ad without Rituximab. (Chi-square, Pearson corrected calculations for all variables, Age, incidence of reactivation and reactviation time: student t-test).